Patient Focused Drug Development: Eczema
As part of the collaboration, we hosted a patient-focused drug development (PFDD) meeting on September 23, 2019 in the Washington, D.C. area. It provided the eczema community an opportunity to speak directly to Food and Drug Administration (FDA) staff, representatives of pharmaceutical and medical device companies, and other key stakeholders.
This initiative was the first of its kind for eczema . Your voice and perspectives are essential for us to demonstrate that eczema is “more than skin deep.”